Form 8-K - Current report:
SEC Accession No. 0001140361-22-002499
Filing Date
2022-01-24
Accepted
2022-01-24 17:00:36
Documents
14
Period of Report
2022-01-18
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10033022_8k.htm   iXBRL 8-K 32595
2 EXHIBIT 16.1 brhc10033022_16-1.htm EX-16.1 3961
6 graphic01.jpg GRAPHIC 8078
  Complete submission text file 0001140361-22-002499.txt   187196

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA btx-20220118.xsd EX-101.SCH 3929
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20220118_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20220118_pre.xml EX-101.PRE 16047
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10033022_8k_htm.xml XML 4246
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 22550108
SIC: 2834 Pharmaceutical Preparations